drugset
drugset / Trial / NCT03088280

Efficacy and Safety of Rabbit Antithymocyte Globulin 3mg/kg in Kidney Transplant Patients Under Steroid-free and CNI Minimization Maintenance Immunosuppressive Regimen

NCT03088280 ↗

Phase 4 Unknown 200 enrolled Hospital Geral de Fortaleza
RandomizedSequentialOpen-labelTreatment

Summary

Single-center, prospective, randomized, open-label clinical trial to evaluate the 1-year efficacy and safety of rATG 3mg/kg compared to 6mg/kg in low to moderate immunological risk patients receiving low exposure tacrolimus plus everolimus (EVL) in a steroid-free protocol.

Timeline

Start
2015-06-30
Primary completion
2018-01-10
Completion
2020-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Thymoglobulin Protein / enzyme biologic 3 mg/kg —
Subject Thymoglobulin Protein / enzyme biologic 6 mg/kg —

Indications

No indication recorded.